Insulin-like growth factor-1, psoriasis, and inflammation: A ménage à trois?

S. Savastano, N. Balato, F. Gaudiello, C. Di Somma, V. Brancato, A. Colao, F. Ayala, Giovanni Tarantino

Research output: Contribution to journalArticlepeer-review


Psoriatic patients have an accumulation of metabolic syndrome (MS) and cardiovascular diseases (CVD), likely mediated by systemic inflammation, and exhibiting low circulating levels of insulin-like growth factor (IGF)-I, a marker of MS and CVD in the general population. The aim of this study is to determine the association of IGF-I and inflammation, and to assess the cardio-metabolic risk calculating the visceral adiposity index (VAI), in a group of psoriatic patients without MS. IGF-I, fibrinogen, C-reactive protein (CRP), and interleukin (IL)-6 levels were determined in 20 patients with moderate to severe psoriasis (age range 23-77 yrs) without MS, according to criteria of the National Cholesterol Education Program's Adult Panel III (ATP III), and 20 age- and BMI-matched controls. The standard deviation score (SDS) of IGF-I levels according to age (zSDS), the homeostasis model assessment of insulin resistance (HOMA-IR), the whole-body insulin sensitivity index (ISI), and VAI were also calculated. Psoriasis Area and Severity Index (PASI) mean value was 17.8±11. HDL cholesterol and IGF-I zSDS values were lower (p

Original languageEnglish
Pages (from-to)277-283
Number of pages7
JournalEuropean Journal of Inflammation
Issue number3
Publication statusPublished - Sep 2011


  • IGF-I
  • Inflammation
  • Metabolic syndrome
  • Psoriasis
  • Visceral adiposity index

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy


Dive into the research topics of 'Insulin-like growth factor-1, psoriasis, and inflammation: A ménage à trois?'. Together they form a unique fingerprint.

Cite this